Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalRegion |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:approvalYear |
2018-08-10
|
| gptkbp:ATCCode |
N07XX12
|
| gptkbp:chemicalClass |
gptkb:small_interfering_RNA_(siRNA)
|
| gptkbp:form |
lipid nanoparticle
|
| gptkbp:genericName |
gptkb:patisiran
|
| https://www.w3.org/2000/01/rdf-schema#label |
ONPATTRO
|
| gptkbp:indication |
hereditary transthyretin-mediated amyloidosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:prescriptionRequired |
https://www.onpattro.com/
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
abdominal pain
flushing arthralgia muscle spasms infusion-related reactions upper respiratory tract infections |
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:target |
gptkb:transthyretin_mRNA
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_ALNY
|
| gptkbp:bfsLayer |
7
|